Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Revenue of AlloVir, Inc. (ALVR)
Revenue in 2023 (TTM): $
According to AlloVir, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of AlloVir, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-398,000 | $-190,146,000 | $-190,544,000 | $-190,418,000 |
| 2022 | $ | $-2,565,000 | $-166,410,000 | $-168,975,000 | $-168,710,000 |
| 2021 | $ | $-1,117,000 | $-169,838,000 | $-170,955,000 | $-171,962,000 |
| 2020 | $ | $-73,000 | $-69,711,000 | $-69,784,000 | $-68,381,000 |
| 2019 | $165 K | $165 K | $-26,682,000 | $-23,839,000 | $-21,774,000 |
| 2018 | $1.14 M | $1.14 M | $-3,596,000 | $-2,430,000 | $-2,430,000 |